Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”

被引：0
|
作者：
John Pixley
机构：
[1] University of Nevada School of Medicine,Division of Rheumatology
[2] University of VA Sierra Heath Care System,Division of Immunology
来源：
Clinical Rheumatology | 2013年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1413 / 1413
相关论文
共 50 条
  • [1] Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases"
    Pixley, John
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1413 - 1413
  • [2] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [3] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [4] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    [J]. Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [5] PRIOR IMMUNOGENICITY TO ANTI-TNF BIOLOGICS IS NOT ASSOCIATED WITH INCREASED ANTI-DRUG ANTIBODIES TO VEDOLIZUMAB OR USTEKINUMAB
    Costable, Nicholas J.
    Borman, Zachary A.
    Phan, Becky L.
    Ji, Jiayi
    Dubinsky, Marla
    Ungaro, Ryan C.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S468 - S469
  • [6] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Costable, Nicholas J.
    Borman, Zachary A.
    Ji, Jiayi
    Dubinsky, Marla C.
    Ungaro, Ryan C.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2480 - 2484
  • [7] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Nicholas J. Costable
    Zachary A. Borman
    Jiayi Ji
    Marla C. Dubinsky
    Ryan C. Ungaro
    [J]. Digestive Diseases and Sciences, 2022, 67 : 2480 - 2484
  • [8] BARRIERS AGAINST TESTING ANTI-TNF DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN ROUTINE CLINICAL PRACTICE
    Gavan, S. P.
    Daker-White, G.
    Payne, K.
    Barton, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1726 - 1727
  • [9] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [10] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
12345